These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis.
    Author: Putzki N, Kollia K, Woods S, Igwe E, Diener HC, Limmroth V.
    Journal: Eur J Neurol; 2009 Mar; 16(3):424-6. PubMed ID: 19187261.
    Abstract:
    BACKGROUND: Natalizumab has been recommended for the treatment of patients with relapsing remitting multiple sclerosis with insufficient response to interferon-beta (IFN-beta) or glatiramer acetate (GA). METHOD: Prospective, observational study. RESULTS: We found a reduction of the annualized relapse rate from 2.1 under IFN-beta or GA to 0.2 one year after switching to natalizumab. There were 94% fewer gadolinium enhancing lesions with natalizumab. CONCLUSION: Natalizumab reduced short term clinical and MRI activity in second line therapy and efficacy is comparable to first line therapy as demonstrated in the pivotal trials.
    [Abstract] [Full Text] [Related] [New Search]